HR陽性、HER2陰性の再発または転移性乳がん患者における内分泌療法と併用したアリセルチブの研究 (ALISCA-Breast1)
HR+、HER2陰性の再発または転移性乳がん患者における内分泌療法と併用したアリセルチブの第2相試験
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) following progression on or after at least two prior lines of endocrine therapy in the recurrent or metastatic setting. This study is intended to evaluate the optimal alisertib dose administered in combination with the selected endocrine therapy. The study is also planned to evaluate the efficacy, safety, and pharmacokinetics of alisertib in combination with endocrine and to identify the biomarker-defined subgroup(s) that may benefit most from combined alisertib and endocrine therapy. Participants randomized prior to Amendment 4 are randomized 1:1:1 to Arm 1, Arm 2 or Arm 3. Participants randomized under Amendment 4 will be randomized 1:1 to Arm 1 or Arm 2.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Puma Biotechnology, Inc. Clinical Operations Senior Director
- 電話番号:424-248-6500
- メール:ClinicalTrials@pumabiotechnology.com
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、34235
- 募集
- Alabama Oncology
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85054
- 募集
- Mayo Clinic Hospital
-
-
California
-
Beverly Hills、California、アメリカ、90211
- 募集
- Beverly Hills Cancer Center
-
Fountain Valley、California、アメリカ、92708
- 募集
- MemorialCare Orange Coast Medical Center
-
Irvine、California、アメリカ、92618
- 募集
- City of Hope at Orange County Lennar Foundation Cancer Center
-
Los Angeles、California、アメリカ、90095
- 募集
- UCLA Department of Medicine - Hematology/Oncology
-
Los Angeles、California、アメリカ、90017
- 募集
- LA Cancer Network
-
San Francisco、California、アメリカ、94158
- 募集
- University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 募集
- University of Colorado School of Medicine
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06520
- 引きこもった
- Yale University, Yale Cancer Center
-
-
Florida
-
Jacksonville、Florida、アメリカ、32256
- 募集
- Cancer Specialists of North Florida
-
Jacksonville、Florida、アメリカ、32224
- 募集
- Mayo Clinic Florida
-
Tampa、Florida、アメリカ、33612
- 募集
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322
- 募集
- Winship Cancer Institute, Emory University
-
-
Illinois
-
Chicago、Illinois、アメリカ、60612
- 募集
- University of Illinois Cancer Center
-
Chicago、Illinois、アメリカ、60637
- 募集
- The University of Chicago
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- 募集
- Massachusetts General Hospital
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Dana-Farber Cancer Institute
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455
- 募集
- University of Minnesota, Masonic Cancer Center
-
Rochester、Minnesota、アメリカ、55905
- 募集
- Mayo Clinic
-
-
Missouri
-
Columbia、Missouri、アメリカ、65201
- 募集
- Missouri Cancer Associates
-
Kansas City、Missouri、アメリカ、64111
- 募集
- Saint Luke's Cancer Institute
-
Springfield、Missouri、アメリカ、65807
- 募集
- Oncology Hematology Associates
-
St Louis、Missouri、アメリカ、63110
- 募集
- Washington University School of Medicine
-
-
Nevada
-
Reno、Nevada、アメリカ、89511
- 募集
- Cancer Care Specialists
-
-
New York
-
Rochester、New York、アメリカ、14642
- 募集
- University of Rochester Medical Center
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27514
- 募集
- UNC Hospitals, University of North Carolina at Chapel Hill
-
-
Ohio
-
Columbus、Ohio、アメリカ、43212
- 募集
- The Ohio State University, Stefanie Spielman Comprehensive Breast Center
-
Maumee、Ohio、アメリカ、43537
- 募集
- Taylor Cancer Research Center
-
-
Pennsylvania
-
Horsham、Pennsylvania、アメリカ、19044
- 募集
- Alliance Cancer Specialists
-
Philadelphia、Pennsylvania、アメリカ、19104
- 募集
- University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine
-
Pittsburgh、Pennsylvania、アメリカ、15213
- 募集
- University of Pittsburgh (UPMC)
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37203
- 募集
- Tennessee Oncology, Greco-Hainsworth Center for Research
-
-
Texas
-
Dallas、Texas、アメリカ、75246
- 募集
- Texas Oncology
-
-
Virginia
-
Richmond、Virginia、アメリカ、23229
- 募集
- Virginia Cancer Institute
-
-
-
-
-
Alicante、スペイン、03010
- 募集
- Hospital General Universitario Dr. Balmis
-
Barakaldo、スペイン、48903
- 募集
- Hospital Universitario de Cruces
-
Barcelona、スペイン、08035
- 募集
- Hospital Universitario Vall d'Hebron
-
Barcelona、スペイン、08036
- 募集
- Hospital Clínico de Barcelona
-
Bilbao、スペイン、48013
- 募集
- Hospital Universitario de Basurto
-
Cáceres、スペイン、10003
- 募集
- Hospital San Pedro de Alcántara
-
Granada、スペイン、18012
- 募集
- Hospital San Cecilio
-
Huelva、スペイン、21005
- 募集
- Hospital Universitario Juan Ramon Jimenez
-
Jaén、スペイン、23007
- 募集
- Hospital Universitario de Jaén
-
Lleida、スペイン、25198
- 募集
- Hospital Universitario Arnau de Vilanova
-
Madrid、スペイン、28040
- 募集
- Hospital Universitario Fundación Jiménez Díaz
-
Seville、スペイン、41013
- 募集
- Hospital Universitario Virgen del Rocío
-
Valencia、スペイン、46010
- 募集
- Hospital Clínico Universitario de Valencia
-
Valencia、スペイン、46009
- 募集
- Fundación Instituto Valenciano de Oncología (IVO)
-
-
-
-
-
Lisbon、ポルトガル、1998-018
- 募集
- Hospital CUF Descobertas
-
Lisbon、ポルトガル、1099-023
- 募集
- Instituto Português de Oncologia de Lisboa Francisco Gentil (IPO Lisboa)
-
Lisbon、ポルトガル、1400-038
- 募集
- Fundação Champalimaud
-
Porto、ポルトガル、4200-072
- 募集
- Instituto Português Oncologia Do Porto
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Aged ≥18 years at signing of informed consent.
- Pathology-confirmed diagnosis of breast cancer with evidence of recurrent or metastatic disease not amenable to curative therapy.
- Progression on or after treatment with at least two prior lines of endocrine therapy in the recurrent or metastatic setting. a. If metastatic disease recurrence occurs during or within six months of discontinuing adjuvant endocrine therapy, then that endocrine therapy will count as one line of prior therapy.
- Participants must have received a CDK4/6i in combination with endocrine therapy in the recurrent or metastatic setting.
- HR-positive and HER2-negative tumor status reported per local laboratory testing. HR and HER2 testing must be performed consistent with current American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) or European Society of Medical Oncology (ESMO) guidelines.
Exclusion Criteria:
- Treatment with chemotherapy in the recurrent or metastatic setting, including antibody drug conjugates with a chemotherapeutic payload.
- Prior treatment with an Aurora Kinase A (AURKA) specific-targeted or pan-Aurora-targeted agent, including alisertib, in any setting.
Note: There are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Alisertib 50 mg
Alisertib with selected endocrine therapy |
Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.
他の名前:
Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information. 1 mg of anastrozole tablet by mouth once daily or 2.5 mg of letrozole tablet by mouth once daily or 25 mg of exemestane tablet by mouth once daily or 20 mg of tamoxifen tablet by mouth once daily or 500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter |
|
実験的:Alisertib 40 mg
Alisertib with selected endocrine therapy |
Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.
他の名前:
Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information. 1 mg of anastrozole tablet by mouth once daily or 2.5 mg of letrozole tablet by mouth once daily or 25 mg of exemestane tablet by mouth once daily or 20 mg of tamoxifen tablet by mouth once daily or 500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter |
|
実験的:Alisertib 30 mg
Alisertib with selected endocrine therapy Cohort closed to enrollment in Amendment 4 |
Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.
他の名前:
Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information. 1 mg of anastrozole tablet by mouth once daily or 2.5 mg of letrozole tablet by mouth once daily or 25 mg of exemestane tablet by mouth once daily or 20 mg of tamoxifen tablet by mouth once daily or 500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate (ORR) Within Dose Subgroup
時間枠:From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
|
Objective response rate is defined as the percentage of participants demonstrating a confirmed objective response during the study. |
From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
|
|
Duration of Response (DOR) Within Dose Subgroup
時間枠:From start date of response (after date of randomization) to first PD, assessed up to 48 months
|
Duration of response is measured from the time at which measurement criteria are first met for Complete Response (CR) or Partial Response (PR) (whichever status is recorded first) until the first date of recurrence or progressive disease (PD) or death is objectively documented. |
From start date of response (after date of randomization) to first PD, assessed up to 48 months
|
|
Disease Control Rate (DCR) Within Dose Subgroup
時間枠:From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
|
Disease control rate is the proportion of participants who achieve overall tumor response (confirmed CR or PR) or Stable Disease (SD) lasting for at least 24 weeks from randomization. |
From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
|
|
Progression Free Survival (PFS) Within Dose Subgroup
時間枠:From date of randomization to date of recurrence, progression or death, assessed up to 48 months
|
Progression Free Survival (PFS) is measured in months and based on the local tumor assessment. The time interval from the date of randomization until the first date on which recurrence, progression, or death due to any cause, is documented. |
From date of randomization to date of recurrence, progression or death, assessed up to 48 months
|
|
Overall Survival (OS) Within Dose Subgroup
時間枠:From date of randomization to death, assessed up to 48 months
|
Overall survival (OS) is defined as the time from randomization to death due to any cause, censored at the last date known alive on or prior to the data cutoff employed for the analysis, whichever was earlier. |
From date of randomization to death, assessed up to 48 months
|
|
Percentage of Participants With Treatment-Emergent Adverse Events (Adverse Events and Serious Adverse Events) in the Enrolled Population
時間枠:From date of first dose through last dose plus 28 days, assessed up to 48 months
|
Treatment emergent adverse events are those events reported on or after the first dose of investigational product and up to 28 days after last dose. |
From date of first dose through last dose plus 28 days, assessed up to 48 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response Rate (ORR) Within Biomarker-Defined Subgroup
時間枠:From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
|
Objective response rate is defined as the percentage of participants demonstrating a confirmed objective response during the study. |
From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
|
|
Duration of Response (DOR) Within Biomarker-Defined Subgroup
時間枠:From start date of response (after date of randomization) to first PD, assessed up to 48 months
|
Duration of response is measured from the time at which measurement criteria are first met for CR or PR (whichever status is recorded first) until the first date of recurrence or progressive disease (PD) or death is objectively documented. |
From start date of response (after date of randomization) to first PD, assessed up to 48 months
|
|
Disease Control Rate (DCR) Within Biomarker-Defined Subgroup
時間枠:From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
|
Disease control rate is the proportion of participants who achieve overall tumor response (confirmed CR or PR) or SD lasting for at least 24 weeks from randomization. |
From date of randomization to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 48 months
|
|
Progression Free Survival (PFS) Within Biomarker-Defined Subgroup
時間枠:From date of randomization to date of recurrence, progression or death, assessed up to 48 months
|
Progression Free Survival (PFS) is measured in months and based on the local tumor assessment. The time interval from the date of randomization until the first date on which recurrence, progression, or death due to any cause, is documented. |
From date of randomization to date of recurrence, progression or death, assessed up to 48 months
|
|
Overall Survival (OS) Within Biomarker-Defined Subgroup
時間枠:From date of randomization to death, assessed up to 48 months
|
Overall survival (OS) is defined as the time from randomization to death due to any cause, censored at the last date known alive on or prior to the data cutoff employed for the analysis, whichever was earlier. |
From date of randomization to death, assessed up to 48 months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Chief Reg Affairs, PV, Medical Affairs and Law Officer、Puma Biotechnology, Inc.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- PUMA-ALI-1201
- 2024-511497-79-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Puma Biotechnology is committed to sharing clinical trial data and information to help physicians and patients make informed treatment decisions, and to help qualified researchers advance scientific knowledge.
In accordance with legal and regulatory requirements, Puma publishes study protocol information and clinical study results on clinical trial registries, including ClinicalTrials.gov and EU Clinical Trials Register. Puma also publishes information about clinical studies in peer-reviewed scientific journals and shares data in scientific meetings.
Puma commits to safeguarding confidentiality and patient privacy throughout the clinical trial data and information sharing process. Any patient-level data will be anonymized to protect personally identifiable information.
Qualified researchers and study participants may submit requests for other study documentation and clinical trial data to clinicaltrials@pumabiotechnology.com for consideration.
IPD 共有時間枠
Clinical study documents and clinical trial data may be requested by qualified researchers and study participants for studies that have been completed for at least 18 months, and for which the indication of the drug has been approved in the US and/or EU, as applicable. Requests will be accepted for up to 24 months after the criteria described in this section are met.
IPD 共有アクセス基準
Requestors must provide organizational contact information; a detailed research plan, including outcomes; timeline for completion of the research; qualifications of the research team; funding source; and potential conflicts of interest.
Puma will not provide access to patient-level data if there is a reasonable likelihood that individual patients could be identified, or in cases where confidentiality or consent provisions prohibit transfer of data or information to third parties. Additionally, Puma will not disclose information that jeopardizes intellectual property rights or divulges confidential commercial information.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。